Microtubules (tau) as an emerging therapeutic target: Nap (davunetide)

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3413-3417

  Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity dependent neuroprotective protein (adnp); Alzheimer's disease; Behavior; Cognition; Davunetide; Developmental disorders; Drug discovery and development; Frontotemporal dementia; Microtubules; Nap; Neurodegeneration; Neuroprotection; Parkinson disease; Progressive supranuclear palsy (psp); Schizophrenia; Tau; Tauopathy; Tubulin

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; DAVUNETIDE; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1ALPHA; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROTROPHIC FACTOR; NOCODAZOLE; PROTEIN; SYNAPTOPHYSIN; TAU PROTEIN; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BRAIN DEVELOPMENT; CELL DISRUPTION; CELL INTERACTION; CELL PROTECTION; CHROMATIN; CHROMOSOMAL LOCALIZATION; COGNITIVE DEFECT; CYTOTOXICITY; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; HAPLOINSUFFICIENCY; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SYNAPSE; TAUOPATHY;

CENTRAL NERVOUS SYSTEM AGENTS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MICROTUBULES; NERVE TISSUE PROTEINS; OLIGOPEPTIDES;

EID: 80055108264     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072553     Document Type: Article

References (62)

1. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 1996; 97: 2299-307.
2. Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996; 7: 235-44.
3. Gozes I, Davidson A, Gozes Y, et al. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res 1997; 99: 167-75.
4. Blondel O, Collin C, McCarran WJ, et al. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000; 20: 8012-20.
5. Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-93.
6. Zusev M, Gozes I. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004; 123: 33-41.
7. Gozes I. Tau pathology and future therapeutics. Curr Alzheimer Res 2010; 7: 685-96.
8. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr Alzheimer Res 2009; 6: 455-60.
9. Pinhasov A, Mandel S, Torchinsky A, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003; 144: 83-90.
10. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 2007; 303: 814-24.
11. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 2007; 282: 34448-56.
12. Mosch K, Franz H, Soeroes S, Singh PB, Fischle W. HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PLoS One 2011; 6: e15894.
13. Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, Gozes I. Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci 2004; 24: 181-7.
14. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005; 2: 149-53.
15. Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 2010; 41: 114-20.
16. Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 2006; 252: 148-53.
17. Zamostiano R, Pinhasov A, Gelber E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001; 276: 708-14.
18. Poggi SH, Goodwin K, Hill JM, et al. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 2003; 189: 790-3.
19. Pascual M, Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem 2007; 103: 557-68.
20. Toso L, Cameroni I, Roberson R, Abebe D, Bissell S, Spong CY. Prevention of developmental delays in a Down syndrome mouse model. Obstet Gynecol 2008; 112: 1242-51.
21. Borozdin W, Graham JM, Jr., Bohm D, et al. Multigene deletions on chromosome 20q13.13-q13.2 including SALL4 result in an expanded phenotype of Okihiro syndrome plus developmental delay. Hum Mutat 2007; 28: 830.
22. Cosgrave AS, McKay JS, Bubb V, Morris R, Quinn JP, Thippeswamy T. Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure. Neurobiol Dis 2008; 30: 281-292.
23. Braitch M, Kawabe K, Nyirenda M, et al. Expression of Activity- Dependent Neuroprotective Protein in the Immune System: Possible Functions and Relevance to Multiple Sclerosis. Neuroimmunomodulation 2009; 17: 120-5.
24. Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. Eur Neuropsychopharmacol 2011; 21: 355-61.
25. Cattano D, Valleggi S, Ma D, et al. Xenon induces transcription of ADNP in neonatal rat brain. Neurosci Lett 2008; 440: 217-21.
26. Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP- family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem 2008; 105: 537-45.
27. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007; 323: 438-49.
28. Furman S, Hill JM, Vulih I, et al. Sexual dimorphism of activity- dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 2005; 373: 73-8.
29. Gennet N, Herden C, Bubb VJ, Quinn JP, Kipar A. Expression of activity-dependent neuroprotective protein in the brain of adult rats. Histol Histopathol 2008; 23: 309-17.
30. Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci 2008; 35: 127-41.
31. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity- Illana Gozes dependent neuroprotective protein in astrocytes. Neuron Glia Biol 2004; 1: 193-9.
32. Underhill C, Qutob MS, Yee SP, Torchia J. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J Biol Chem 2000; 275: 40463-70.
33. Dellaire G, Makarov EM, Cowger JJ, et al. Mammalian PRP4 kinase copurifies and interacts with components of both the U5 snRNP and the N-CoR deacetylase complexes. Mol Cell Biol 2002; 22: 5141-56.
34. de Barreda EG, Dawson HN, Vitek MP, Avila J. Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron- specific gene repression. FEBS Lett 2010; 584: 2265-70.
35. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998; 53: 127-40.
36. Gozes I. Davunetide (NAP) pharmacology: Neuroprotection and tau. In: Martinez A, editor. Emerging Drugs and Targets for Alzheimer's Disease. 1st ed. Cambridge: Royal Society of Chemistry, 2010: 108-28.
37. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004; 279: 28531-8.
38. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 2006; 98: 973-84.
39. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007; 4: 507-9.
40. Zemlyak I, Sapolsky R, Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol 2009; 618: 9-14.
41. Zemlyak I, Sapolsky R, Gozes I. NAP protects against cyanide- related microtubule destruction. J Neural Transm 2009; 116: 1411-1416.
42. Shiryaev N, Pickman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (Davunetide) and D-SAL: Biochemical, cellular and behavioral aspects. Curr Pharm Design 2011; In Press.
43. Sudo H, Baas PW. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet 2011; 20: 763-78.
44. Visochek L, Steingart RA, Vulih-Shultzman I, et al. PolyADP- ribosylation is involved in neurotrophic activity. J Neurosci 2005; 25: 7420-8.
45. Lagreze WA, Pielen A, Steingart R, et al. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 2005; 46: 933-8.
46. Gozes I, Spivak-Pohis I. Neurotrophic effects of the peptide NAP: A novel neuroprotective drug candidate. Curr Alzheimer Res 2006; 3: 197-9.
47. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-Dependent Neurotrophic Factor-9 and NAP Promote Neurite Outgrowth in Rat Hippocampal and Cortical Cultures. J Mol Neurosci 2005; 25: 225-38.
48. Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 2004; 6: S37-41.
49. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-8.
50. Matsuoka Y, Gray A, Hirata-Fukae C, Sakura Minami S, Graeme Waterhouse E, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007; 31: 165-170.
51. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-53.
52. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides 2010; 31: 1368-73.
53. Gozes I. Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides 2011; 32: 428-31.
54. Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, et al. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 2009; 111: 1252-63.
55. Fleming SM, Mulligan CK, Richter F, et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2010.
56. Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Neuroscience 2011; 173: 156-68.
57. Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rosner M. Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol 2011; 89: e126-31. Received: July 25, 2011 Accepted: August 17, 2011 Current Pharmaceutical Design, 2011, Vol. 17, No. 31 3417
58. Sharma NK, Sethy NK, Meena RN, Ilavazhagan G, Das M, Bhargava K. Activity-dependent neuroprotective protein (ADNP)- derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides 2011.
59. Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005; 11: 353-68.
60. Schmechel D, Gerard G, Vatakis NG, et al. A phase 2, double- blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Alzheimer's & Dementia 2008; 4: T483.
61. Javitt DC. Effects of intranasal AL-108 (davunetide) on neurocognition and functional outcome in schizopherenia. Schizophrenia Research 2010; 117: 118-9.
62. Morimoto BH, de Lannoy I, Fox AW, Gozes I, Stewart AJ. Davunetide: Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. chimica Oggi/CHEMISTRY today 2009; 27: 16-20.